Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial.
about
Management of Chemotherapy Induced Nausea and Vomiting in Patients on Multiday Cisplatin Based Combination ChemotherapyPalonosetron in the prevention of chemotherapy-induced nausea and vomiting: an evidence-based review of safety, efficacy, and place in therapyTreatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and VomitingEvolving treatment paradigms for chemotherapy-induced nausea and vomitingNeurokinin-1 inhibitors in the prevention of nausea and vomiting from highly emetogenic chemotherapy: a network meta-analysisRecent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive reviewDelayed Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Incidence, and Current ManagementMe, TooCheaper Options in the Prevention of Chemotherapy-Induced Nausea and Vomiting.Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomitingPalonosetron in the management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day chemotherapy.Management of chemotherapy-induced nausea and vomiting : focus on newer agents and new uses for older agents.The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.Chemotherapy-induced nausea and vomiting #285.Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV)Incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant.Prophylactic treatment for delayed chemotherapy-induced nausea and vomiting after non-AC based moderately emetogenic chemotherapy: a systematic review of randomized controlled trialsPrevention of cisplatin-based chemotherapy-induced delayed nausea and vomiting using triple antiemetic regimens: a mixed treatment comparisonChemotherapy-Induced Nausea and Vomiting: Time for More Emphasis on Nausea?Efficacy of Olanzapine Combined Therapy for Patients Receiving Highly Emetogenic Chemotherapy Resistant to Standard Antiemetic Therapy.Ramosetron Versus Ondansetron in Combination With Aprepitant and Dexamethasone for the Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Randomized Phase III Trial, KCSG PC10-21.Comparison of the Control of Nausea and Vomiting among Several Moderately Emetic-Risk Chemotherapy Regimens.A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy.Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients.Differential pharmacology and clinical utility of rolapitant in chemotherapy-induced nausea and vomiting.Olanzapine for the Prevention of Chemotherapy-Induced Nausea and VomitingDifferential clinical pharmacology of rolapitant in delayed chemotherapy-induced nausea and vomiting (CINV)Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK1) receptor antagonists.A meta-analysis of olanzapine for the prevention of chemotherapy-induced nausea and vomitingSafety of neurokinin-1 receptor antagonists.Palonosetron for the prevention of chemotherapy-induced nausea and vomiting.Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review.Meta-analysis of adjunctive non-NK1 receptor antagonist medications for the control of acute and delayed chemotherapy-induced nausea and vomiting.Palonosetron for the treatment of chemotherapy-induced nausea and vomiting.Olanzapine for treatment and prevention of acute chemotherapy-induced vomiting in children: a retrospective, multi-center review.Olanzapine in the treatment of refractory nausea and vomiting: a case report and review of the literature.Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.Chemotherapy-induced nausea and vomiting: an overview and comparison of three consensus guidelines.State of the Art Antiemetic Therapy for Cancer Patients.The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting.
P2860
Q26783177-169E35F2-3DBC-402D-A041-A5FF42DB158CQ26783229-AF00572A-8F24-4940-ABC3-777009A9823FQ26784070-349664C7-99D2-48A3-97CF-8D1E0D0744BFQ27024463-99AFE692-8995-4878-A40A-216B1DA4ED39Q28078513-621F4FC4-4CE3-4E14-B139-501BE7379479Q28081186-7E4B3824-561D-4973-9B26-8078BD960D8FQ30235971-F4E9EE67-0B02-4EC0-9655-912110B443CAQ33866095-606225A3-93A9-4F9F-AA2E-19FF8C647C5EQ33866119-B7EF2FA9-E077-4A8E-AB35-1D9E46892009Q33886138-9E4042B6-CFA3-4578-B748-FBB620450A86Q34166946-D3B6D92C-294B-4433-8CAC-8FEBB2071077Q34327488-92B97CA2-82E7-4FA4-B94B-160A0E4E4E45Q34647257-AE279644-A8EA-479F-8823-8B24090B702DQ34719140-B383186A-C859-402C-A808-A5360D33234CQ34775395-960C9581-D491-4A97-9E28-8CF18648E8D1Q34778628-37C1BAF2-1AAE-4CAE-BD73-3344B4AF39CEQ35789229-888FE0B1-A67C-44F9-82FE-556626B6E381Q35970506-35037F03-1DE0-467C-B6BA-C13A4859A8EFQ36064834-43C94A31-C426-4C25-A079-E1E2CD209A0CQ36070497-25FC49A9-818A-483C-8600-18D096878CBEQ36371595-0EAB3CC3-0F3D-4FA0-ADFA-7BAC55D43DD3Q36764931-3D7A1C9D-C2AD-43F4-9D9B-C1A6BD6C2C8FQ37111164-733D58C9-A2BA-4D60-85D3-FA79DC3CFA58Q37609798-806DDD6D-E0FC-448F-889C-D13FF8B16F35Q37669043-B1062051-F80A-40F0-9342-684849F8A092Q37691654-15849CC8-88D6-4F8D-9697-A37D6908352AQ37730595-03D20C89-B36B-428A-B4AF-4850681F66D4Q37736060-11A4DDFD-4398-4B42-88F3-EA462200E7ACQ37738165-3AF50FBF-2843-4353-9C8F-B7FFFDAC4778Q38109245-2D312319-EE6D-4111-BA82-BB149759DF8BQ38132238-79479890-056B-4DD9-8D56-7277CF49B380Q38187578-64DDD44C-2B59-429B-9889-ECA6A7C9705BQ38241998-82BCB6DA-CF1D-43B6-BB6B-BC57482A8EF9Q38260952-A459C445-B835-4697-8E1E-6530024C4E65Q38261290-0E25806A-45BB-45E4-9C97-177D96A0ABE9Q38533535-657678D0-5102-4CDA-AE75-8F0FA3DB1E13Q38574240-EB955730-3768-4E3A-81BC-E98701FA5D18Q38631646-90ACCD18-AD4D-442B-B26B-ADAAD79B08E9Q38676452-EF61FDB7-ED23-44ED-9ED6-19453FB7ABD5Q38677762-82B9E28C-8370-496D-8A26-12B9873F4365
P2860
Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial.
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Olanzapine versus aprepitant f ...... a randomized phase III trial.
@ast
Olanzapine versus aprepitant f ...... a randomized phase III trial.
@en
Olanzapine versus aprepitant f ...... a randomized phase III trial.
@nl
type
label
Olanzapine versus aprepitant f ...... a randomized phase III trial.
@ast
Olanzapine versus aprepitant f ...... a randomized phase III trial.
@en
Olanzapine versus aprepitant f ...... a randomized phase III trial.
@nl
prefLabel
Olanzapine versus aprepitant f ...... a randomized phase III trial.
@ast
Olanzapine versus aprepitant f ...... a randomized phase III trial.
@en
Olanzapine versus aprepitant f ...... a randomized phase III trial.
@nl
P2093
P1476
Olanzapine versus aprepitant f ...... a randomized phase III trial.
@en
P2093
Andrew C Kerr
Rudolph M Navari
Sarah E Gray
P304
P356
10.1016/J.SUPONC.2011.05.002
P577
2011-09-24T00:00:00Z